AADIGEN LLC and DIVINCELL SAS are sister BioPharmaceutical companies, specializing in the development of unique and innovative solutions for targeted RNA therapeutic delivery in the treatment of cancers and genetic diseases.
AADIGEN was founded in 2012 by Neil Desai, PhD and DIVINCELL was cofounded by Gilles Divita, PhD and Neil Desai in 2018. The company’s platform technology based on amphipathic peptides and their use in the delivery of oligonucleotides and is based on the original research and invention of Gilles Divita. The company has established an unique intellectual property platform, know-how and expertise based on over 25 years of research in the field of nanomedicine and drug delivery.
Our versatile breakthrough technology offers innovative and unique solutions to tackle the major stumbling block in RNA therapeutics which continues to be the systemic targeting and cellular-release of RNA-based agents and provides an effective drug delivery system for a wide range of clinical applications and pathologies
Our focus in cancer is based on a unique two pronged approach - TUMOR SUPPRESSOR RESCUETM (TSG-RESCUETM, TSG-RESQTM) and ONCOGENE EDITINGTM (ONCOEDITTM). These approaches have been validated by numerous studies in therapeutic cancer models including lung cancer, colorectal cancer, pancreatic cancer and osteosarcoma.
Our focus in other diseases has been validated by studies in therapeutic models including reversal of hemophilia and hypercholesterolemia using our technology.
